| Identification | Back Directory | [Name]
Clonitrazolam | [CAS]
33887-02-4 | [Synonyms]
Clonazolam
Clonitrazolam
Clonazolam (CRM)
Clonazolam solution
Clonazolam, 8-Nitrodeschlorotriazolam, Clonitrazolam
8-Nitro-6-(2-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine
8-Nitro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine
6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 6-(2-chlorophenyl)-1-methyl-8-nitro-
6-(2-chloro-phenyl)-1-methyl-8-nitro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine | [Molecular Formula]
C17H12ClN5O2 | [MOL File]
33887-02-4.mol | [Molecular Weight]
353.76 |
| Chemical Properties | Back Directory | [Boiling point ]
576.0±60.0 °C(Predicted) | [density ]
1.53±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [form ]
A neat solid | [pka]
1.88±0.40(Predicted) |
| Hazard Information | Back Directory | [Description]
Clonazolam (CRM) (Item No. 25614) is a certified reference material categorized as a benzodiazepine. It is also categorized as a sedative and has been abused recreationally. This product is intended for research and forensic applications. | [Description]
Clonazolam is a benzodiazepine that was developed as a central nervous system depressant in the 1970s and has recently emerged as a drug of abuse. It potently antagonizes convulsions induced by thiosemicarbazide and pentobarbital (ED50s = 90 μg/kg for both agonists in mice). In vitro phase I metabolites of clonazolam, derived from human liver microsomes, have been described. This product is intended for forensic and research applications. | [Uses]
8-Nitro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine can be used as a central nervous system depressant. | [References]
[1] BJOERN MOOSMANN Volker A Leslie A King. Designer benzodiazepines: A new challenge.[J]. World Psychiatry, 2015, 14 2: 248. DOI: 10.1002/wps.20236
[2] KIERAN R. MANCHESTER. The emergence of new psychoactive substance (NPS) benzodiazepines: A review[J]. Drug Testing and Analysis, 2017, 10 1: 37-53. DOI: 10.1002/dta.2211 |
|